Viewpoint Molecular Targeting(TM) Awarded $5 Million in Phase II SBIR Grants from the National Institutes of Health - National Cancer Institute

- $2 million Phase II SBIR grant awarded to advance image-guided alpha-particle therapy for metastatic melanoma and radioisotope production technologies - Second year of a $2 million Phase II SBIR funding to begin a Phase 1 clinical imaging trial of complementary Pb-203 and Ga-68 diagnostics for metastatic melanoma - $2 million Phase II Small Business Innovation Research (SBIR) grant awarded to fund development activities and advance preclinical studies of VMT-